Cullinan Therapeutics (CGEM) investor relations material

Executive summary

• Focused on developing first- or best-in-class therapies for autoimmune diseases and cancer, leveraging T cell engager expertise and a clinical-stage pipeline advancing multiple programs.

• Initial clinical data for CLN-978 in SLE and RA to be presented at EULAR 2026; multi-dose RA data expected in Q3 2026.

• Zipalertinib NDA for relapsed EGFR ex20ins NSCLC accepted by FDA; PDUFA date set for February 27, 2027.

• Cash and investments of $393.3 million as of March 31, 2026, providing runway into 2029.

• Multiple upcoming catalysts and milestones across the pipeline anticipated through 2026 and beyond.

Financial highlights

• Cash, cash equivalents, investments, and interest receivable totaled $393.3 million at March 31, 2026, down from $438.9 million at December 31, 2025.

• Net loss for Q1 2026 was $49.7 million, compared to $48.5 million in Q1 2025.

• Research and development expenses were $42.1 million for Q1 2026, up from $41.5 million in Q1 2025.

• General and administrative expenses were $11.6 million for Q1 2026, down from $13.5 million in Q1 2025.

• No products approved or revenue from product sales; operations funded primarily through equity and licensing.

Outlook and guidance

• Cash resources expected to provide operational runway into 2029 under the current plan.

• Ongoing and planned clinical data readouts for key programs (CLN-978, velinotamig, CLN-049, zipalertinib) throughout 2026.

• Zipalertinib regulatory milestones expected, with potential for $130 million in milestone payments and U.S. profit share.

• No revenue expected from product sales for several years.